The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...

Kidney failure, known in medical circles as end-stage renal disease (ESRD), casts a heavy shadow over Black folks in the ...

The Ridin’ For Kids Foundation has announced the child that will be benefiting from their 2025 fundraiser event.

If you experience persistent muscle weakness, fatigue and skin changes that don't seem to fade, it could be more than just ...

Hereditary predisposition is a relevant cause of cancer in children and adolescents. At least 10% of all pediatric tumors are due to germline mutations in cancer predisposition genes. Although Cancer ...

Several known risk factors of Dermatomyositis (DM) include female sex, genetics, ultraviolet radiation, prior respiratory disease, viral and bacterial infections, medications, and pollutants and ...

She carried binders of medical records to doctors' appointments across six health systems seeking the best care for juvenile dermatomyositis. She volunteered at a nonprofit searching for a cure.